Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Investing Activities (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Cash from Investing Activities data on record, last reported at $16.0 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 695.7% year-over-year to $16.0 million; the TTM value through Sep 2025 reached -$69.0 million, down 5267.37%, while the annual FY2024 figure was -$116.2 million, 2374.45% down from the prior year.
  • Cash from Investing Activities reached $16.0 million in Q3 2025 per CAPR's latest filing, up from $14.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $23.9 million in Q1 2025 and bottomed at -$123.4 million in Q4 2024.
  • Average Cash from Investing Activities over 5 years is -$4.9 million, with a median of -$322459.0 recorded in 2021.
  • The widest YoY moves for Cash from Investing Activities: up 1494.77% in 2022, down 10882.05% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$368671.0 in 2021, then skyrocketed by 1494.77% to $5.1 million in 2022, then crashed by 214.01% to -$5.9 million in 2023, then plummeted by 2004.53% to -$123.4 million in 2024, then surged by 112.93% to $16.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $16.0 million in Q3 2025, $14.5 million in Q2 2025, and $23.9 million in Q1 2025.